𝛼SK or Searchbullish
Artrya (ASX:AYA): SAPPHIRE strong market strategy getting noticed
SUMMARY
- SAPPHIRE: Connecting Salix with the best in cardiac medicine First announced in February 2025, the three-phase Salix-based Analysis of Plaque to identify Patients at HIgher Risk of Events (SAPPHIRE) study is a retrospective study examining whether AI-driven analysis is a superior predictor of heart attacks compared to current standard-of-care risk models.
- SAPPHIRE puts Salix into the hands of major potential customers SAPPHIRE partners are not only large, but also prestigious.
- The study includes Mass General, one of the most prestigious hospital groups and medical research institutions in the world.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Artrya (ASX:AYA): SAPPHIRE strong market strategy getting noticed08 Feb 2026
x